Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body’s response to injury.
aCT1 is a patented new chemical entity currently in development for multiple indications. The Company’s lead clinical programs include Granexin® gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.
Company Details
- Employees
- 6
- Address
- 777 Taylor St., Fort Worth,texas 76102,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.xequel.com
- Keywords
- Charleston.
- HQ
- Fort Worth, Texas
Xequel Bio Questions
Xequel Bio's website is http://www.xequel.com
Xequel Bio's LinkedIn profile is https://www.linkedin.com/company/xequel-bio
Xequel Bio has
6 employees.
View email and phone details for 6
employees at Xequel Bio.
Xequel Bio's industry is
Biotechnology Research
Xequel Bio's top competitors are
Chrysalis Biotherapeutics, Inc.,
Polyactiva,
Melt Pharmaceuticals,
Alimera,
Immunomet Therapeutics, Inc.,
Santen,
Crossject,
Lowcountry Center For Veterans Research,
Eledon Pharmaceuticals, Inc.,
Sca Pharma.
Xequel Bio's categories are Biotechnology Research
